Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: Analysis of the National Cancer Data Base

Journal of Clinical Oncology

Volumn 33, Issue 6, 2015, Pages 625-633

  Olszewski, Adam J ^a,b   Shrestha, Rajesh ^a,b   Castillo, Jorge J ^c  

^a BROWN UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLACK PERSON; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; DATA BASE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INSURANCE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNINSURED; MULTIMODALITY CANCER THERAPY; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; SOCIAL STATUS; TREATMENT INDICATION; UNITED STATES; ADOLESCENT; AGE; MIDDLE AGED; PATHOLOGY; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; HODGKIN DISEASE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84923135400     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.7543     Document Type: Article

References (51)

1. Siegel R, DeSantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220-241, 2012
2. Noordijk EM, Carde P, Dupouy N, et al: Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128-3135, 2006
3. Fermé C, Eghbali H, Meerwaldt JH, et al: Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357:1916-1927, 2007
4. Follows GA, Ardeshna KM, Barrington SF, et al: Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol 166:34-49, 2014
5. Hoppe RT, Advani RH, Bierman PJ, et al: Hodgkin disease/lymphoma: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:210-230, 2006
6. Engert A, Plutschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
7. Canellos GP, Abramson JS, Fisher DC, et al: Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 28:1611-1615, 2010
8. Herbst C, Rehan FA, Brillant C, et al: Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: A systematic review. Haematologica 95:494-500, 2010
9. Meyer RM, Gospodarowicz MK, Connors JM, et al: ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 366:399-408, 2012
10. Thomas RK, Re D, Zander T, et al: Epidemiology and etiology of Hodgkin's lymphoma. Ann Oncol 13:147-152, 2002 (suppl 4)
11. Shenoy P, Maggioncalda A, Malik N, et al: Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv Hematol 2011:725219, 2011
12. US Census Bureau: Health Insurance Coverage of Young Adults Aged 19 to 25: 2008, 2009, and 2011. Washington, DC, US Census Bureau, 2012
13. Aizer AA, Falit B, Mendu ML, et al: Cancer-specific outcomes among young adults without health insurance. J Clin Oncol 32:2025-2030, 2014
14. Smith EC, Ziogas A, Anton-Culver H: Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer 118:6179-6187, 2012
15. Koshy M, Rich SE, Mahmood U, et al: Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys 82:619-625, 2012
16. Olszewski AJ, Desai A: Radiation therapy administration and survival in stage I/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int J Radiat Oncol Biol Phys 88:642-649, 2014
17. Bilimoria KY, Stewart AK, Winchester DP, et al: The National Cancer Data Base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15:683-690, 2008
18. Bilimoria KY, Bentrem DJ, Stewart AK, et al: Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: Implications for studies that use the National Cancer Data Base. J Clin Oncol 27:4177-4181, 2009
19. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
20. White IR, Royston P, Wood AM: Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30:377-399, 2011
21. van der Heijden GJ, Donders AR, Stijnen T, et al: Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: A clinical example. J Clin Epidemiol 59:1102-1109, 2006
22. Brown H, Prescott R: Generalised Linear Mixed Models, Applied Mixed Models in Medicine. New York, NY, John Wiley & Sons, 2006, pp 107-152
23. Hardy D, Chan W, Liu CC, et al: Racial disparities in the use of hospice services according to geographic residence and socioeconomic status in an elderly cohort with nonsmall cell lung cancer. Cancer 117:1506-1515, 2011
24. McNutt LA, Wu C, Xue X, et al: Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 157:940-943, 2003
25. Giobbie-Hurder A, Gelber RD, Regan MM: Challenges of guarantee-time bias. J Clin Oncol 31:2963-2969, 2013
26. Mitra R, Reiter JP: A comparison of two methods of estimating propensity scores after multiple imputation. Stat Methods Med Res [epub ahead of print on June 11, 2012]
27. Armstrong K: Methods in comparative effectiveness research. J Clin Oncol 30:4208-4214, 2012
28. Hernán MA: Beyond exchangeability: The other conditions for causal inference in medical research. Stat Methods Med Res 21:3-5, 2012
29. Cole SR, Hernán MA: Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168:656-664, 2008
30. Austin PC: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083-3107, 2009
31. Royston P, Parmar MK: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 21:2175-2197, 2002
32. Nelson CP, Lambert PC, Squire IB, et al: Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 26:5486-5498, 2007
33. Rutherford MJ, Dickman PW, Lambert PC: Comparison of methods for calculating relative survival in population-based studies. Cancer Epidemiol 36:16-21, 2012
34. Stürmer T, Rothman KJ, Avorn J, et al: Treatment effects in the presence of unmeasured confounding: Dealing with observations in the tails of the propensity score distribution - A simulation study. Am J Epidemiol 172:843-854, 2010
35. Lin DY, Psaty BM, Kronmal RA: Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54: 948-963, 1998
36. Klimm B, Goergen H, Fuchs M, et al: Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: An analysis of international staging definitions. Ann Oncol 24:3070-3076, 2013
37. Hébert-Croteau N, Brisson J, Latreille J, et al: Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 22:3685-3693, 2004
38. Chagpar R, Xing Y, Chiang YJ, et al: Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol 30:972-979, 2012
39. Tao L, Foran JM, Clarke CA, et al: Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood 123:3553-3562, 2014
40. Flowers CR, Fedewa SA, Chen AY, et al: Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev 21:1520-1530, 2012
41. Keegan TH, Clarke CA, Chang ET, et al: Disparities in survival after Hodgkin lymphoma: A population-based study. Cancer Causes Control 20: 1881-1892, 2009
42. Evens AM, Antillón M, Aschebrook-Kilfoy B, et al: Racial disparities in Hodgkin's lymphoma: A comprehensive population-based analysis. Ann Oncol 23:2128-2137, 2012
43. Ng AK, Kuntz KM, Mauch PM, et al: Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 50:979-989, 2001
44. Lauzier S, Levesque P, Drolet M, et al: Out-of-pocket costs for accessing adjuvant radiotherapy among Canadian women with breast cancer. J Clin Oncol 29:4007-4013, 2011
45. Raemaekers JM, André MP, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188-1194, 2014
46. Evens AM, Hong F, Gordon LI, et al: The efficacy and tolerability of Adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: A comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161:76-86, 2013
47. Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
48. nd planned interim analysis of the RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a "negative" FDG-PET scan after 3 cycles ABVD. Blood 112:369, 2008 (abstr)
49. Meyer RM, Hoppe RT: Point/counterpoint: Early-stage Hodgkin lymphoma and the role of radiation therapy. Blood 120:4488-4495, 2012
50. Yahalom J: Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but "same" (or possibly worse) survival - Reconsidering the misguided trend to omit radiotherapy. Curr Hematol Malig Rep 9:212-216, 2014
51. Campbell BA, Hornby C, Cunninghame J, et al: Minimising critical organ irradiation in limited stage Hodgkin lymphoma: A dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 23:1259-1266, 2012